Nuclear receptors as drug targets for metabolic disease

Adv Drug Deliv Rev. 2010 Oct 30;62(13):1307-15. doi: 10.1016/j.addr.2010.07.002. Epub 2010 Jul 22.

Abstract

Nuclear hormone receptors comprise a superfamily of ligand-activated transcription factors that control development, differentiation, and homeostasis. Over the last 15 years a growing number of nuclear receptors have been identified that coordinate genetic networks regulating lipid metabolism and energy utilization. Several of these receptors directly sample the levels of metabolic intermediates including fatty acids and cholesterol derivatives and use this information to regulate the synthesis, transport, and breakdown of the metabolite of interest. In contrast, other family members sense metabolic activity via the presence or absence of interacting proteins. The ability of these nuclear receptors to impact metabolism will be discussed and the challenges facing drug discovery efforts for this class of targets will be highlighted.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Drug Discovery
  • Energy Metabolism
  • Humans
  • Ligands
  • Lipid Metabolism
  • Liver X Receptors
  • Metabolic Diseases / drug therapy*
  • Metabolic Diseases / metabolism*
  • Molecular Targeted Therapy*
  • Neoplasms / chemically induced
  • Orphan Nuclear Receptors / agonists
  • Orphan Nuclear Receptors / genetics
  • Orphan Nuclear Receptors / metabolism*
  • Peroxisome Proliferator-Activated Receptors / agonists
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Peroxisome Proliferator-Activated Receptors / metabolism*
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Signal Transduction

Substances

  • Ligands
  • Liver X Receptors
  • Orphan Nuclear Receptors
  • Peroxisome Proliferator-Activated Receptors
  • Receptors, Cytoplasmic and Nuclear